Skip to main content

Table 2 Characteristics of the included studies

From: The effects of several postoperative adjuvant therapies for hepatocellular carcinoma patients with microvascular invasion after curative resection: a systematic review and meta-analysis

Author, year Country Study design Variety of analysis Intervention Case (n) BCLC AFP Age (year) Male Curative resection Follow up months Outcome NOS score
Xiao, 2019 [14] China RS (PSM) MA Re-resection/RFA 49 BCLC B-C 22  > 200 32.7% NR 43 yes 84 OS 5
Pa-TACE: carboplatin 300 mg, epirubicin 50 mg, mytomycin C 8 mg 49 BCLC B-C 25  > 200 38.8% NR 46 yes 84 OS
Wang, 2018 [11] China RS (PSM) MA Conservation 57 BCLC B 10  > 200 40% 56 ± 10 51 yes 60 OS, RFS 7
Pa-TACE: fluorouracil 750 mg, epirubicin 40 mg or pharmorubici 40 mg 57 BCLC B 11  > 200 44% 55 ± 11 47 yes 60 OS, RFS
Wang, 2019 [12] China RS (PSM) MA Radiotherapy: 54–60 Gy 46 NR  > 400 22% 50.98 ± 10.53 43 yes 100 OS, RFS 8
Pa-TACE: doxorubicin 20–30 mg 46 NR  > 400 15% 51.52 ± 11.40 37 yes 100 OS, RFS
Wei, 2018 [15] China RCT UA Conservation 118 NR  ≥ 25 69.5% 48.5 (18–74) 106 yes 72 OS. RFS  
Pa-TACE: carboplatin 200 mg, mitomycin 6 mg, epirubicin 40 mg 116 NR  ≥ 25 68.1% 44 (18–75) 106 yes 72 OS, RFS
Wang, 2018 [16] China RS MA Conservation 84 NR 367.45 ± 474.58 54.49 ± 10.18 76 yes 84 OS, RFS 8
Pa-TACE: doxorubicin 10 mg or pharmorubicin 20–40 mg 44 NR 357 ± 444.12 52.07 ± 7.27 42 yes 84 OS, RFS
Ye, 2017 [17] China RS MA Conservation 174 BCLC B 47  > 400 48.9%  > 60 19.5% 150 yes 60 OS, RFS 8
Pa-TACE: lobaplatin 50 mg, raltitrexed 4 mg 86 BCLC B 16  > 400 43%  > 60 15.1% 75 yes 60 OS, RFS
Wang, 2017 [13] China RS MA Conservation 50 NR  > 400 36% 57.22 ± 11.14 5 yes 60 OS, RFS 7
Pa-TACE: adriamycin 20–30 mg 42 NR  > 400 40.5% 51.38 ± 10.89 8 yes 60 OS, RFS
Radiotherapy: 54–60 Gy 44 NR  > 400 22.7% 51.32 ± 11.21 5 yes 60 OS, RFS
Liu, 2016 [18] China RS UA Conservation 159 BCLC B 12  > 400 57.2% 53 ± 11.8 125 yes 60 OS, RFS 8
Pa-TACE: fluorouracil 750 mg, epirubicin 40 mg or pharmorubici 40 mg 137 BCLC B 16  > 400 49.6% 49 ± 10.6 134 yes 60 OS, RFS
Sun, 2015 [19] China RS MA Conservation 185 BCLC A/B 98  > 400 49.2% 49.91 ± 0.72 167 yes 120 OS, RFS 8
Pa-TACE: doxorubicin 10 mg or pharmorubicin 20–40 mg 137 BCLC A/b 76  > 400 42.3% 48.88 ± 0.87 120 yes 120 OS, RFS
Liu, 2016 [20] China RS UA Conservation 26 NR NR NR NR yes 40 RFS 5
Pa-TACE: fluorouracil 1000 mg, oxaliplatin 100 mg, epirubicin 40–60 mg 24 NR NR NR NR yes 40 RFS
Jin, 2014 [21] Korea RS UA Resection/RFA 8 NR NR NR NR yes 96 OS 5
Pa-TACE: cisplatin 0.5 mg 23 NR NR NR NR yes 96 OS
Huang, 2019 [23] China RS MA Conservation 33 BCLC B 12.5%  > 400 42.42% 51.52 ± 11.87 30 yes 72 OS, RFS 7
Sorafenib 16 BCLC B 12.1%  > 400 50% 52.25 ± 11.94 12 yes 72 OS, RFS
Qi, 2018 [22] China RS UA Conservation 109 BCLC B 33  > 400 45.8% NR 93 yes 36 OS, RFS 7
TACE:lobaplatin (25–100 mg) + pharmorubici (10–50 mg) 91 BCLC B 37  > 400 48.4% NR 78 yes 36 OS, RFS
  1. Pa-TACE postoperative adjuvant transarterial chemoembolization, PSM propensity score matching, RCT randomized clinical trial, RFA radiofrequency ablation ablation, MA multivariate analysis, UA univariate analysis, RS retrospective study